Market Insights on GLP-1 Trials and Small Business Outlook

This chapter examines the market reactions to the clinical trial data for Amgen's GLP-1 drug, Meritide, highlighting stock performance and investor sentiment. It also delves into Paychex's financial situation post-acquisition and discusses the current economic landscape for small businesses amidst wage inflation and Federal Reserve challenges. Engaging with callers, the hosts offer rapid financial advice, analyzing various companies to guide listeners on stock opportunities.